Key result
In patients with atrial fibrillation taking direct-acting oral anticoagulants, severe obesity was not associated with a higher risk of stroke or systemic embolism compared to normal BMI.
Why the study?
Limited data exist on the efficacy and safety of fixed-dose direct-acting oral anticoagulants in severe obesity, where altered pharmacokinetics and pharmacodynamics may occur.
Does severe obesity alter the efficacy and safety of direct-acting oral anticoagulants for stroke prevention in patients with atrial fibrillation?
Cohort (n=7,642)
Yes
Does severe obesity alter the efficacy and safety of direct-acting oral anticoagulants for stroke prevention in patients with atrial fibrillation?
Answers are grounded in this paper and cite their sources.
Direct-acting oral anticoagulants maintain similar efficacy and safety profiles for stroke prevention in atrial fibrillation across all BMI categories, supporting their use without dose adjustment even in severe obesity.
Background Direct‐acting oral anticoagulants are now the preferred method of anticoagulation in patients with atrial fibrillation. Limited data on efficacy and safety of these fixed‐dose regimens are available in severe obesity where drug pharmacokinetics and pharmacodynamics may be altered. The objectives of this study were to evaluate efficacy and safety in patients with atrial fibrillation taking direct‐acting oral anticoagulants across body mass index (BMI) categories in a contemporary, real‐world population. Methods and Results We performed a retrospective study of patients with atrial fibrillation at an integrated multisite healthcare system. Patients receiving a direct‐acting oral anticoagulant prescription and ≥12 months of follow‐up between 2010 and 2017 were included. The primary efficacy and safety outcomes were ischemic stroke or systemic embolism and intracranial hemorrhage. We performed Cox proportional hazards modeling to compute hazard ratios (HRs) adjusted for CHA 2 DS 2 ‐VASc score to examine differences by excess BMI categories relative to normal BMI. Of 7642 patients, mean±SD age was 69±12 years with a median (interquartile range) follow‐up of 3.8 (2.2–6.0) years. Approximately 22% had class 1 obesity and 19% had class 2 or 3 obesity. Stroke risks were similar in patients with and without obesity (HR, 1.2; 95% CI, 0.5–2.9; and HR, 0.68; 95% CI, 0.23–2.0 for class 1 and class 2 or 3 obesity compared with normal BMI, respectively). Risk of intracranial hemorrhage was also similar in class 1 and class 2 or 3 obesity compared with normal BMI (HR, 0.64; 95% CI, 0.35–1.2; and HR, 0.66; 95% CI, 0.35–1.2, respectively). Conclusions Direct‐acting oral anticoagulants demonstrated similar efficacy and safety across all BMI categories, even at high weight values.
No takes yet. Share an insight, caveat, or question.
Kaplan et al. (2020) conducted a cohort in Atrial Fibrillation (n=7,642). Class 2 or 3 Obesity (BMI ≥35 kg/m2) vs. Normal BMI (18.5-24.9 kg/m2) was evaluated on Ischemic stroke or systemic embolism (HR 0.68, 95% CI 0.23-2.0, p=0.490). In patients with atrial fibrillation taking direct-acting oral anticoagulants, severe obesity was not associated with a higher risk of stroke or systemic embolism compared to normal BMI.
Synapse has enriched 10 related papers. Consider them for comparative context: